



BERYL DRUGS LIMITED

Regd. Off.: Ground Floor, 133, Kanchan Bagh, Indore - 452001 (M.P.) INDIA.

Tel. : (0731) 2517677 E-mail : beryldrugs25@yahoo.com **CIN : L02423MP1993PLC007840**

Date: 12th February, 2019

To,

The Secretary,
Department of Corporate Services,
Bombay Stock Exchange Limited (BSE),
Phiroze Jeejeebhoy Towers, Dalal Street,
Mumbai – 400001

Sub.: Disclosure of Regulation 30 read with Part- A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Dear Sirs,

Pursuant to Regulation 30 read with Part- A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform that the Board of Directors in its Board Meeting held on 12.02.2019 has approved the Unaudited Financial Results of the Company for the Quarter ended 31st December, 2018.

We hereby request you to kindly acknowledge the receipts of same.

Thanking You,

Yours Sincerely

For Beryl Drugs Limited



Sudhir Sethi
Chairman & Director
DIN: 00090172



BERYL DRUGS LIMITED
Gr. Floor, 133, Kanchan Bagh, Indore (M.P.) – 452 001.
Tel./ Fax 0731-2517677
E-mail : beryldrugs25@yahoo.com

ANNEXURE I

Part I Submission of Unaudited/ Audited Financial Result by Companies Other than Banks

Statement of standalone Unaudited Result for the Quarter/ year ended 31/12/2018 (Rs in 000)

Particulars	Quarter ended			Third Quarter ended		Year ended
	3 months ended (31.12.2018)	Preceding 3 months ended (30-09-2018)	Corresponding 3 months ended in the previous year (31-12-2017)	Year to date figures for current period ended (31-12-2018)	Year to date figures for previous period ended (31-12-2017)	Previous year ended (31-03-2018)
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1 Revenue From Operations						
Net sales or Revenue from Operations	30636.000	35071.000	36309.000	107109.000	116963.000	152487.000
Other operating revenues	-526.000	888.000	36.000	833.000	628.000	6948.000
Total Revenue from operations (net)	30110.000	35959.000	36345.000	107942.000	117591.000	159435.000
2 Expenses						
(a) Cost of materials consumed	14127.000	19591.000	25732.000	55529.000	74861.000	88279.000
(b) Purchases of stock-in-trade	0.000	0.000	0.000	0.000	0.000	0.000
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-608.000	-1516.000	-119.000	2184.000	12240.000	4459.000
(d) Employee benefit expense	2462.000	2192.000	2084.000	6562.000	5459.000	7704.000
(e) Finance costs	749.000	598.000	212.000	1739.000	903.000	1323.000
(f) Depreciation and amortisation expense	705.000	416.000	1000.000	2121.000	3000.000	3297.000
(g) Other Expenses	10653.000	12129.000	6112.000	32712.000	17980.000	41638.000
Total expenses	28088.000	33410.000	35021.000	100847.000	114443.000	146700.000
3 Profit (loss) from operations before exceptional items and tax	2022.000	2549.000	1324.000	7095.000	3148.000	12735.000
4 Exceptional items	0.000	0.000	0.000	0.000	4568.000	0.000
5 Profit (loss) before tax	2022.000	2549.000	1324.000	7095.000	7716.000	12735.000
6 Tax Expense						
Current tax	509.000	794.000	300.000	1803.000	920.000	2418.000
Income tax earlier years	-32.000	0.000	0.000	0.000	0.000	0.000
Deferred tax	105.000	347.000	0.000	452.000	0.000	388.000
Total Tax Expenses	582.000	1141.000	300.000	2223.000	920.000	2806.000
7 Net Profit (loss) for the period from continuing operations	1440.000	1408.000	1024.000	4872.000	6796.000	9929.000
8 Net Profit (loss) from discontinuing operations before tax	0.000	0.000	0.000	0.000	0.000	0.000
9 Tax Expense of discontinuing operations	0.000	0.000	0.000	0.000	0.000	0.000
10 Net Profit (loss) from discontinuing operations after tax	0.000	0.000	0.000	0.000	0.000	0.000
11 Net Profit (loss) for the Period	1440.000	1408.000	1024.000	4872.000	6796.000	9929.000
12 Other comprehensive income	-834.000	3851.000	0.000	3017.000	0.000	-2125.000
13 Total Comprehensive Income	606.000	5259.000	1024.000	7889.000	6796.000	7804.000
14 Details of equity share capital						
Paid-up equity share capital	50717.000	50717.000	50717.000	50717.000	50717.000	50717.000
Face value of equity share capital	10.000	10.000	10.000	10.000	10.000	10.000
15 Earnings per share (for continuing operation)						
i Basic earnings per share	0.284	0.278	0.202	0.961	1.340	1.958
ii Diluted earnings per share	0.284	0.278	0.202	0.961	1.340	1.958
16 Earnings per share (for discontinued operation)						
i Basic earnings per share	0.000	0.000	0.000	0.000	0.000	0.000
ii Diluted earnings per share	0.000	0.000	0.000	0.000	0.000	0.000
17 Earnings per share (for discontinued and continuing operation)						
i Basic earnings per share	0.284	0.278	0.202	0.961	1.340	1.958
ii Diluted earnings per share	0.284	0.278	0.202	0.961	1.340	1.958

Notes :

- The Quarterly results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their respective meeting held on 12 Feb 2019. The Statutory Auditors have carried out a limited review of the results for the quarter ended Dec 31, 2018.
- This statement has been prepared in accordance with the Companies (Indian Accounting Standard) Rules, 2015 (Ind AS) PRESCRIBED UNDER SECTION 133 OF THE Companies Act, 2013, & other recognized accounting practices & policies to the extent applicable.
- The Income from Operations is from one segment namely "Pharmaceutical Industry".
- Previous period expenses have been regrouped / rearranged, wherever necessary.
- Taxes and Depreciation are calculated on proportionate basis on annual estimated basis.
- The Company's management has exercised necessary due diligence to ensure that such financial results provide a true and fair view of its affairs.
- The other comprehensive items comprises of the loss arising due to revaluation of investment made in Equity Shares of Beryl Securities Ltd.

Place : Indore
Date : 12/02/2019

For and behalf of the Board
Director
Sanjay Sethi
Managing Director

PRATEEK JAIN & CO.


CHARTERED ACCOUNTANTS

212, SHALIMAR CORPORATE CENTRE, 8-B, SOUTH TUKOGANJ,

INDORE (M.P.) 452001

PH. 9827013187, 0731-2520955

E-MAIL: caprateekjain@gmail.com



LIMITED REVIEW REPORT

To,
The Board of Directors
Beryl Drugs Limited
133, Kanchan Bagh,
Indore (M.P.) - 452001

We have reviewed the accompanying statement of unaudited financial results of **BERYL DRUGS LIMITED** ("the Company") for the quarter ended **31st December, 2018** and the year to date results for the period 1st April 2018 to 31st December 2018 attached herewith, being submitted by the Company pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410 "*Review of Interim Financial Information performed by Independent auditor of the Entity*" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement.

A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable Indian Accounting Standards ("Ind AS") prescribed under section 133 of the Companies Act, 2013 read with relevant rules there under and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

FOR- PRATEEK JAIN AND CO.
CHARTERED ACCOUNTANTS
FRN-009494C



Prateek Jain
PRATEEK JAIN
PROPRIETOR
M. No. 079214

Date: 12th February, 2019

Place: Indore